Therapeutic Neuromuscular Disorders
Feb 05, 2008 at 16:24
Nov 12, 2007 at 16:24
Nov 06, 2007 at 11:45
Sep 20, 2007 at 17:25
Nov 16, 2006 at 17:28
Photos »
/ 
Related News »
The ALS Therapy Development Institute and Neurotune established a collaboration to evaluate one of the latter’s neuromuscular diseases candidates ... for the treatment of nervous system disorders including sarcopenia (age-related loss of ...
May 15, 2012 at 12:33 | Source: Genetic Engineering News
“Thus, at this time, more studies are needed to definitively conclude that vitamin D can offer preventive and therapeutic ... disorders.” The scientific statement outlines the evidence to suggest the effects of vitamin D on epidermal, neuromuscular ...
May 22, 2012 at 01:05 | Source: Nutra Ingredients
Vinik, M.D., Ph.D., FCP, MACP, Director of Research and Neuroendocrine Unit at Strelitz Diabetes Center for Endocrine and Metabolic Disorders at Eastern ... in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.
May 17, 2012 at 19:48 | Source: Marketwatch
It is also quite effective for Neuropathies, headaches, and other neurological conditions or disorders. DTS Spinal Decompression ... moist heat therapy, neuromuscular rehabilitation and a therapeutic exercise rehabilitation program as well as spinal ...
May 21, 2012 at 15:11 | Source: Emailwire
Maintaining connectivity at this "neuromuscular junction" is crucial to a person's ... ALS TDI collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, Aestus Therapeutics, MDA and ...
May 14, 2012 at 19:51 | Source: Phramalive.com
As such, with few treatment options available for these patients, there is a high unmet need for new therapeutic options to address ... muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase II clinical ...
May 9, 2012 at 11:29 | Source: Yahoo Finance
As such, with few treatment options available for these patients, there is a high unmet need for new therapeutic options to address ... muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase II clinical development ...
May 9, 2012 at 12:26 | Source: 4-traders (press release)